Novotalk

Company Overview

Snapshot

Founded in March 2014, Novotalk operates with 1–10 employees. The company has secured funding across three rounds from Mount Sinai Ventures and Millhouse Capital. A significant milestone for Novotalk was its joint venture agreement with Mount Sinai Health System in July 2018 for commercialization in North America and future research and development collaborations.

Business overview

Novotalk develops on-demand, self-directed speech and language teletherapy solutions designed to help individuals with speech impairments achieve and maintain intelligible speech remotely. Its core product is a patented web and mobile application that provides self-directed speech therapy, initially available in Hebrew and English. The company serves patients, healthcare providers, and educational institutions, operating within the Digital Health and Medical Technologies sector, with a focus on Digital Therapeutics and Artificial Intelligence.

Strategic signal

In July 2018, Novotalk entered a joint venture agreement with Mount Sinai Health System. This strategic partnership is crucial for Novotalk's expansion, providing a pathway for commercialization in North America and fostering future research and development collaborations. This signals strong institutional validation and a significant step towards broader market penetration for its digital therapy solutions.

Company Intelligence Q&A

What is Novotalk's primary offering?

Novotalk provides on-demand, self-directed speech and language teletherapy solutions through a patented web and mobile application, enabling individuals with speech impairments to practice and maintain fluent speech independently.

When was Novotalk founded?

Novotalk was founded in March 2014.

What significant partnership did Novotalk establish in 2018?

In July 2018, Novotalk signed a joint venture agreement with Mount Sinai Health System for commercialization in North America and future research and development collaborations.